Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...
News Medical on MSN
Customizable protein platforms offer new hope for cancer treatment
Precise methods for shredding or repairing and replacing specific cancer-causing proteins in a malignant cell, developed at the University of Massachusetts Amherst, could have applications beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback